New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 23, 2014
04:55 EDTDNA, DNA, DNA, AMGN, AMGN, AMGN, PFE, PFE, PFE, BIO, BIO, BIO, BIIB, BIIB, BIIB, MRK, MRK, MRK, ASTX, ASTX, ASTX, SNY, SNY, SNY, GSK, GSK, GSKCambridge Healthtech Institute to hold a conference
9th Annual Drug Discovery Chemistry Conference is being held in San Diego, CA on April 23-25.
News For DNA;AMGN;PFE;BIO;BIIB;MRK;ASTX;SNY;GSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
November 12, 2014
09:16 EDTGSKLigand reports GlaxoSmithKline EU regulatory submission for Revolade
Subscribe for More Information
08:53 EDTGSKGlaxoSmithKline weakness creates buying opportunity, says Argus
After GlaxoSmithKline cut its near-term EPS guidance, Argus still believes that the company's deals with Novartis (NVS) should boost its EPS growth in the years ahead, likely as soon as 2015. The firm thinks the stock is a good value for long-term investors, and it keeps a Buy rating on the shares.
08:18 EDTGSKUBS to hold a conference
Subscribe for More Information
08:13 EDTMRK, PFE, SNY, DNA, BIIBBoston Biotech to hold a conference
Subscribe for More Information
08:02 EDTPFECredit Suisse to hold a conference
Subscribe for More Information
07:22 EDTBIOAssociation of Molecular Pathology is holding annual meeting
2014 Annual Meeting of AMP is being held in National Harbor, Maryland on November 12-15.
November 11, 2014
16:05 EDTAMGNAmgen, AstraZeneca say Phase 3 brodalumab study met endpoints
Subscribe for More Information
16:01 EDTMRKOptions Update; November 11, 2014
Subscribe for More Information
15:43 EDTMRK, PFELeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
10:44 EDTAMGNAmgen reaffirms 2015 adjusted EPS outlook $9.05-$9.40
Subscribe for More Information
10:14 EDTSNYRegeneron data reinforce blockbuster potential of dupilumab, says Piper Jaffray
Piper Jaffray believes the Phase IIb results for dupilumab in patients with moderate to severe asthma reported by Regeneron (REGN) and partner Sanofi (SNY) reinforce the broad potential of the drug in a range of allergic diseases. The firm reiterates its $416 price target and Overweight rating on shares of Regeneron.
09:37 EDTMRKActive equity options trading
Subscribe for More Information
08:10 EDTMRKMerck reports results from Phase 2 study of Grazoprevir/Elbasvir
Subscribe for More Information
05:26 EDTSNYRegeneron, Sanofi announce dupilumab Phase 2b study met primary endpoint
Subscribe for More Information
November 10, 2014
16:07 EDTGSKUBS to hold a conference
UBS European Conference is being held in London, England on November 11-12.
15:54 EDTAMGN, SNY, DNAAmerican Society of Nephrology to hold a conference
Subscribe for More Information
09:20 EDTMRKOn The Fly: Pre-market Movers
Subscribe for More Information
08:48 EDTMRKGilead rises after Merck presents data on HCV combo
Subscribe for More Information
07:20 EDTMRKGilead overhang from Merck HCV combo removed, says Wells Fargo
Subscribe for More Information
November 9, 2014
18:58 EDTMRKMerck presents interim data from C-SWIFT study
Merck announced the presentation of interim data from the C-SWIFT study exploring the potential of a candidate triple-therapy regimen consisting of the fixed-dose combination of grazoprevir/elbasvir , the company’s investigational NS3/4A protease inhibitor and NS5A inhibitor, in combination with sofosbuvir, a nucleotide inhibitor for the treatment of chronic hepatitis C virus, HCV, infection. Preliminary findings in treatment-naïve HCV genotype 1- infected non-cirrhotic patients, following six and four weeks of treatment, and patients with cirrhotic disease, following eight and six weeks of treatment, will be presented by Dr. Eric Lawitz, vice president, scientific and research development, The Texas Liver Institute, San Antonio, TX and C-SWIFT lead investigator. This poster presentation is part of a late-breaking abstract session at the 65th American Association for the Study of Liver Diseases, AASLD, Annual Meeting, also known as The Liver Meeting. “These interim data provide a compelling proof-of-concept for the potential of an eight- or six-week triple therapy course in treatment-naive patients with genotype 1 disease, including cirrhotic patients,” said Dr. Lawitz. “These findings will inform the design of larger studies aimed at understanding the potential of short-duration triple therapy across multiple patient types.”
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use